<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04789317</url>
  </required_header>
  <id_info>
    <org_study_id>CRI050</org_study_id>
    <nct_id>NCT04789317</nct_id>
  </id_info>
  <brief_title>Pullback Pressure Gradient (PPG) Global Registry</brief_title>
  <acronym>PPG Global</acronym>
  <official_title>Pullback Pressure Gradient (PPG) Global Registry: Prospective Evaluation of the Impact of the PPG Index on Clinical Decision Making and Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VZW Cardiovascular Research Center Aalst</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VZW Cardiovascular Research Center Aalst</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the predictive capacity of the Pullback Pressure&#xD;
      Gradient (PPG) index for post-PCI FFR and to determine the impact of the PPG index on&#xD;
      clinical decision making about revascularization and on clinical outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Fractional Flow Reserve (FFR) evaluation comprises measurement of a distal single value and&#xD;
      a pullback maneuver during hyperemic conditions. The PPGindex is a novel metric derived from&#xD;
      the FFR pullback curve.3 This metric complements the distal FFR value by informing the&#xD;
      spatial distribution of epicardial resistance (i.e. focal or diffuse) along the coronary&#xD;
      vessel. The PPGindex relies on two components: first, the magnitude of pressure drop&#xD;
      determined as a maximal pressure gradient over 20 millimeters relative to the total vessel&#xD;
      gradient; and second, the length of functional disease relative to total vessel length. These&#xD;
      two parameters are weighted equally to provide a metric that ranges from 0 to 1. PPGindex&#xD;
      values approaching 1 represent functional focal coronary artery disease (CAD) whereas values&#xD;
      close to 0 represent diffuse functional CAD. Until now, the interpretation of the FFR&#xD;
      pullback relied on visual assessment. The PPGindex quantifies the pattern of functional CAD&#xD;
      and has been shown to predict functionally complete revascularization. Percutaneous&#xD;
      revascularization in vessels with high PPGindex is associated with high post-PCI FFR and vast&#xD;
      improvement in epicardial conductance whilst PCI in vessels with low PPGindex results in low&#xD;
      post-PCI FFR. An curvilinear relationship is observed between PPGindex and functional gain&#xD;
      (i.e. FFR post-PCI minus FFR pre-PCI). The PPGindex, therefore, aims to predict the response&#xD;
      to PCI in physiological terms.&#xD;
&#xD;
      Calculation of the PPGindex is indicated in cases with an FFR≤0.80. FFR pullbacks are&#xD;
      performed under hyperemic conditions at a steady pace during manual pullback. A calculation&#xD;
      of the PPGindex using the Coroflow console (Coroventis Research Ab, Uppsala, Sweden) is&#xD;
      available for online use and computes the PPG value immediately after the pullback maneuver.&#xD;
      This software also includes an automated drift correction. The pullback curve is depicted on&#xD;
      an dedicated pullback display screen and the pressure gradients are shown per millimeter,&#xD;
      allowing correlation between the location of pressure step-ups and the anatomical target for&#xD;
      PCI. In summary, we can distinguish three points where FFR influences the clinical&#xD;
      decision-making process. First, an FFR ≤0.80 indicates potential benefit of&#xD;
      revascularization. Second, the pullback curve assesses disease pattern and PPG index value&#xD;
      quantifies it, helping de physician in the decision about treatment options (e.g. PCI, CABG&#xD;
      or OMT). And, third, the location of pressure step-ups along the vessels helps plan the PCI&#xD;
      strategy with respect to coverage of functional disease. A combined FFR and PPG-guided PCI&#xD;
      strategy has the potential to improve patient selection and enhance procedural planning.&#xD;
&#xD;
      The purpose of this study is to determine the predictive capacity of the PPG index for&#xD;
      post-PCI FFR and to determine the impact of the PPG index on clinical decision making about&#xD;
      revascularization and on clinical outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 23, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Predictive capacity of the PPG index for post-PCI FFR.</measure>
    <time_frame>1 year</time_frame>
    <description>Describe the relationship between pre PCI PPG and post-PCI FFR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the relationship between baseline PPG index and major adverse cardiovascular events (cardiac death, peri-procedural and spontaneous myocardial infarction and target vessel revascularization) at one, two and three years.</measure>
    <time_frame>3 years after completion of inclusion</time_frame>
    <description>Assess whether the PPG and identification of CAD endo-type has a relationship with per and post-procedure events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference between baseline and 12 month follow-up in the Seattle Angina Questionnaire (SAQ) stratified by PPG index.</measure>
    <time_frame>1 years after completion of inclusion</time_frame>
    <description>Assess the relationship with symptoms assessed by the SAQ and PPG and persistent/recurrent angina post-PCI</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Rate of patients with intended PCI but deferred after PPG calculation.</measure>
    <time_frame>1 year</time_frame>
    <description>Assess the influence of pullback and PPG on identification of patterns of CAD and change in treatment strategy</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">982</enrollment>
  <condition>Chronic Coronary Insufficiency</condition>
  <condition>Non ST Elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Stable CAD or stabilized NSTEMI (ACS) with significant epicardial lesions defined as FFR≤0.80.</arm_group_label>
    <description>The PPG Global Registry an investigator-initiated, observational, multicenter study of patients with an indication for PCI based on coronary angiography and FFR ≤0.80. After confirmation of intention to treat with PCI, a manual pullback with PPG analysis will be performed. A second level of decision making is then performed concerning PCI, coronary artery bypass grafting (CABG) or medical therapy (OMT). Patients will undergo PCI at operator discretion and post-PCI FFR will be measured. Clinical follow-up will be performed at 1, 2 and 3 years.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive patients with stable coronary artery disease or stabilized acute coronary&#xD;
        syndrome and indication for hemodynamic assessment by FFR and subsequent confirmation of&#xD;
        significant epicardial CAD assessed by an invasive FFR measurement ≤0.80.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Consecutive patients with stable coronary artery disease or stabilized acute coronary&#xD;
             syndrome and invasive FFR measurement ≤0.80.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Angiographic exclusion criteria&#xD;
&#xD;
               1. Ostial lesions.&#xD;
&#xD;
               2. Severe vessel tortuosity.&#xD;
&#xD;
               3. Vessel rewiring deemed 'difficult' by the operator.&#xD;
&#xD;
               4. Bifurcation with planned two-stent strategy.&#xD;
&#xD;
               5. NSTEMI culprit vessel.&#xD;
&#xD;
               6. STEMI&#xD;
&#xD;
               7. Uncontrolled or recurrent ventricular tachycardia.&#xD;
&#xD;
               8. Hemodynamic instability&#xD;
&#xD;
               9. Severe renal dysfunction, defined as an eGFR &lt;30 mL/min/1.73 m2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Collet, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OLV Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carlos Collet, MD PhD</last_name>
    <phone>003253721927</phone>
    <email>carloscollet@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeroen Sonck, MD</last_name>
    <phone>003253727048</phone>
    <email>jeroensonck@icloud.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Hermann Texas Medical Center</name>
      <address>
        <city>Texas City</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Monash Medical Center</name>
      <address>
        <city>Melbourne</city>
        <state>Clayton VIC</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brian Ko, MD</last_name>
      <phone>+61 1300 643 278</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>OLV-Aalst</name>
      <address>
        <city>Aalst</city>
        <state>Oost-Vlaanderen</state>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeroen CS Sonck, MD</last_name>
      <phone>003253724433</phone>
      <email>jeroen.sonck@olvz-aalst.be</email>
    </contact>
    <investigator>
      <last_name>Carlos A Collet, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernard De Bruyne, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Barbato Emanuele, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wyffels Eric, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bartunek Jozef, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Cardiologico Monzino</name>
      <address>
        <city>Milan</city>
        <zip>20138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonio Bartorelli, MD, PhD</last_name>
      <phone>+39 02 580021</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Showa University Hospital</name>
      <address>
        <city>Shinagawa</city>
        <state>Tokyo</state>
        <zip>1420064</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Toshiro Shinke, MD, PhD</last_name>
      <phone>+81337848000</phone>
      <email>shinke@med.showa-u.ac.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Glasgow</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 8QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Colin Berry, Md, PhD</last_name>
      <phone>01413301671</phone>
      <email>Colin.Berry@glasgow.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>King's College London</name>
      <address>
        <city>London</city>
        <zip>WC2R 2LS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Divaka Perera</last_name>
      <phone>+44 (0) 20 7188 1048</phone>
      <email>divaka.perera@kcl.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Collet C, Sonck J, Vandeloo B, Mizukami T, Roosens B, Lochy S, Argacha JF, Schoors D, Colaiori I, Di Gioia G, Kodeboina M, Suzuki H, Van 't Veer M, Bartunek J, Barbato E, Cosyns B, De Bruyne B. Measurement of Hyperemic Pullback Pressure Gradients to Characterize Patterns of Coronary Atherosclerosis. J Am Coll Cardiol. 2019 Oct 8;74(14):1772-1784. doi: 10.1016/j.jacc.2019.07.072.</citation>
    <PMID>31582137</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 26, 2021</study_first_submitted>
  <study_first_submitted_qc>March 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2021</study_first_posted>
  <last_update_submitted>March 4, 2021</last_update_submitted>
  <last_update_submitted_qc>March 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FFR</keyword>
  <keyword>PPG</keyword>
  <keyword>PCI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Non-ST Elevated Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

